Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 70/100

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

Wednesday, November 12, 2025 1 min read
Key Takeaway: Eton Pharmaceuticals will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025. The company's executive leadership team will host one-on-one meetings during the event. Eton specializes in developing treatments for rare diseases and has several products currently on the market and in development.
Price reaction · baseline $17.46 (2025-11-12 close) · hit after-hours · clean, no other ETON news in the window
day 0 close · peak
-3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is actively participating in industry conferences.
  • The company is focused on rare diseases, indicating a niche market.
  • Eton has a robust pipeline with multiple products in late-stage development.

Full Press Release Details

DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference being held November 18, 2025 in New York, NY.
To schedule a 1x1 meeting with the Company, please contact your Craig-Hallum institutional sales representative.
About Eton PharmaceuticalsEton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO®hydrocortisone autoinjector. For more information, please visit our website atwww.etonpharma.com.

Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E:lwilson@insitecony.com

Source: Eton Pharmaceuticals.

Frequently Asked Questions

When is the Craig-Hallum Alpha Select Conference?

The conference is scheduled for November 18, 2025.

What is Eton Pharmaceuticals focused on?

Eton Pharmaceuticals focuses on developing treatments for rare diseases.

How can I schedule a meeting with Eton?

Contact your Craig-Hallum institutional sales representative to schedule a meeting.

What products does Eton Pharmaceuticals have?

Eton has eight commercial products for rare diseases and five in late-stage development.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals Craig-Hallum rare diseases pharmaceutical conference
Last updated: Nov 12, 2025

Biotech snapshot

Cash runway
$20M liquidity · $0M/mo burn
Low dilution risk

Catalyst track record

+165%
best trade around ETON's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ETON.

See every catalyst's timing & PoA →